Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

3.95
+0.930030.79%
Post-market: 4.770.8200+20.76%19:59 EST
Volume:76.07M
Turnover:277.81M
Market Cap:3.89B
PE:-9.51
High:3.99
Open:3.14
Low:3.07
Close:3.02
52wk High:4.27
52wk Low:1.83
Shares:984.97M
Float Shares:194.00M
Volume Ratio:3.29
T/O Rate:39.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4153
EPS(LYR):-0.5931
ROE:78.05%
ROA:-36.89%
PB:-7.42
PE(LYR):-6.66

Loading ...

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 14, 2025

Is ImmunityBio’s (IBRX) Shrinking Losses Evidence of an Emerging Turnaround Story?

Simply Wall St.
·
Nov 08, 2025

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 05, 2025

ImmunityBio Q3 revenue jumps on ANKTIVA demand

Reuters
·
Nov 05, 2025

ImmunityBio Q3 EPS $(0.07) Beats $(0.10) Estimate, Sales $32.061M Beat $31.880M Estimate

Benzinga
·
Nov 05, 2025

Driven by Strong Demand, Immunitybio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, up 434% From Q3 2024

THOMSON REUTERS
·
Nov 05, 2025

Immunitybio Q3 Net Income USD -67.274 Million

THOMSON REUTERS
·
Nov 05, 2025

Press Release: Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Dow Jones
·
Nov 05, 2025

ImmunityBio Board Approves Corporate Amendments

Reuters
·
Oct 21, 2025

ImmunityBio Board Approves Amendment to Increase Authorized Common Stock

Reuters
·
Oct 09, 2025

Columbia Banking System Among 3 Stocks Estimated To Be Undervalued

Simply Wall St.
·
Sep 20, 2025

Why ImmunityBio (IBRX) Is Up 8.3% After Promising ANKTIVA Data in Advanced Lung Cancer

Simply Wall St.
·
Sep 15, 2025

ImmunityBio Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 10, 2025

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Sep 08, 2025

BRIEF-ImmunityBio’s ANKTIVA® Improves Survival in Advanced NSCLC by Reversing Lymphopenia

Reuters
·
Sep 08, 2025

ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients

Reuters
·
Sep 08, 2025

Immunitybio’s Anktiva® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

THOMSON REUTERS
·
Sep 08, 2025

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 27, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Trump Media, Gold miners, Cracker Barrel

Reuters
·
Aug 26, 2025

BUZZ-ImmunityBio on positive early data for cancer treatment regimen

Reuters
·
Aug 26, 2025